electroCore, Inc. ECOR
6.52 USD -1.20 (-15.50%)
Nov 12, 2026, 10:25 AM EST
6.37 Day range 7.92
4.41 52-week range 12.70
- YTD
- +45.10%
- 1 year
- +7.51%
News
zacks.com electroCore (ECOR) Upgraded to Buy: Here's What You Should Know electroCore (ECOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
globenewswire.com electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum ROCKAWAY, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in…
benzinga.com CORRECTION: electroCore Widens FY2026 Sales Guidance from $41.600M to $39.000M-$42.000M vs $41.915M Est electroCore (NASDAQ:ECOR) widens FY2026 sales outlook from $41.600 million to $39.000 million-$42.000 million vs $41.915 million estimate.
benzinga.com electroCore Q3 2026 Earnings Call Transcript electroCore (NASDAQ:ECOR) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com electroCore Raises FY2026 Sales Guidance from $41.600M to $41.642M vs $41.915M Est electroCore (NASDAQ:ECOR) raises FY2026 sales outlook from $41.600 million to $41.642 million vs $41.915 million estimate.
benzinga.com electroCore Q3 EPS $(0.13) Beats $(0.27) Estimate, Sales $9.690M Miss $10.928M Estimate electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.27) by 51.85 percent. This is a 67.5 percent increase over losses of $(0.40)…- benzinga.com electroCore Submits Premarket Notification Seeking Clearance From FDA For Its Quell Wearable Neuromodulation Platform To Treat Chronic Chemotherapy-Induced Peripheral Neuropathy electroCore, Inc. (NASDAQ:ECOR), ("electroCore" or the "Company"), a bioelectronic technology company, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug
benzinga.com Full Transcript: electroCore Q2 2026 Earnings Call electroCore (NASDAQ:ECOR) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by…
benzinga.com electroCore Appoints Joshua Lev, Mike Fox As Co-CEOs, Effective Sept. 8 electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced that it has appointed…
benzinga.com electroCore Lowers FY2026 Sales Guidance from $41.642M to $41.600M vs $41.921M Est electroCore (NASDAQ:ECOR) lowers FY2026 sales outlook from $41.642 million to $41.600 million vs $41.921 million estimate.- benzinga.com electroCore Q2 EPS $(0.33) Beats $(0.40) Estimate, Sales $9.450M Miss $9.491M Estimate electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.40) by 17.5 percent. This is a 25 percent increase over losses of $(0.44) per…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $2.5 million. Tvardi Therapeutics…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market session. The market value of their outstanding shares is at $74.6 million. BNB Plus (NASDAQ:BNBX) stock…
- benzinga.com electroCore Announces Publication Of New Clinical Findings For Quell Device, A Wearable Stimulation Device For The Treatment Of Fibromyalgia The publication in JAMA Network Open, titled, "Transcutaneous Electrical Nerve Stimulation and Pain With Movement in People With Fibromyalgia: A Cluster Randomized Clinical Trial."The study evaluated…
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com electroCore Affirms FY2026 Sales Guidance of $41.642M vs $41.957M Est electroCore (NASDAQ:ECOR) affirms FY2026 sales outlook from $41.642 million to $41.642 million vs $41.957 million estimate.
benzinga.com electroCore Q1 EPS $(0.59) Misses $(0.51) Estimate, Sales $9.584M Beat $9.012M Estimate electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.51) by 15.69 percent. This is a 25.53 percent decrease over losses of…
benzinga.com electroCore Announces New Clinical Findings Published That Demonstrates Potential Benefits Of Adjunctive Non-invasive Vagus Nerve Stimulation In Patients With Chronic Mild Traumatic Brain Injury And Comorbid Post-traumatic Stress Disorder The publication reports results from a post-hoc analysis of 35 patients with chronic mTBI and PTSD. The analysis showed that adjunctive nVNS significantly reduced overall symptom burden, with…
benzinga.com electroCore Announces Issuance Of Two New Additions To U.S. Patent Portfolio U.S. Patent No. 12,208,263, entitled "Devices and Methods for Vagal Nerve Stimulation" was issued on January 28, 2026U.S. Patent No. 12,213,795, entitled "Devices and Methods for Remote Therapy and…- benzinga.com Earnings Scheduled For March 26, 2026
benzinga.com electroCore Q4 EPS $(0.34) Beats $(0.41) Estimate, Sales $9.200M Beat $9.039M Estimate electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.41) by 16.46 percent. This is a 15 percent increase over losses of $(0.40)…- benzinga.com ElectroCore CEO Dan Goldberger To Retire On April 1; Joshua Lev Appointed Interim President, CFO; Michael Fox Appointed COO electroCore, Inc. (Nasdaq: ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced full year 2025 financial results.Announced Chief Executive Officer, Dan…
- benzinga.com Earnings Scheduled For March 19, 2026
benzinga.com HC Wainwright & Co. Maintains Buy on electroCore, Lowers Price Target to $18 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains electroCore (NASDAQ:ECOR) with a Buy and lowers the price target from $25 to $18.- benzinga.com electroCore Announces Acacia Clinics And The Vagus Nerve Society Launch New Research Initiative To Mull Gammacore Sapphire Use As Treatment For Symptoms Associated With PTSD electroCore, Inc. (Nasdaq: ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society have launched a new research…
- benzinga.com electroCore Anticipates Reporting FY25 Revenue Of ~$31.8M-$32M; Estimates Q4 Revenue To Be ~$9M-$9.2M Record revenue of approximately $31.8 - $32.0 million for full-year 2025 and approximately $9.0 - $9.2 million for the three months ended December 31, 2025 Revenue growth of approximately 26% over…
- benzinga.com ElectroCore Granted Patent # US 12469610 B2 For "SYSTEMS AND METHODS FOR TREATING BLOOD CLOTS WITH NERVE STIMULATION" https://ppubs.uspto.gov/api/pdf/downloadPdf/12469610?requestToken=eyJzdWIiOiIzZTQ5MWI5NS0wZjI4LTQwYjQtOGIyNS05ZmVhNTU3MDU1MjYiLCJ2ZXIiOiJmYWMyMzBiNS1kYjU1LTQwZjMtYTA3Yi1lZTY3MjNlY2U5ZDAiLCJleHAiOjB9
- benzinga.com electroCore Q3 EPS $(0.40), Inline, Sales $8.700M Beat $7.843M Estimate electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.40) per share which met the analyst consensus estimate. This is a 29.03 percent decrease over losses of $(0.31) per share from the same…
benzinga.com Earnings Scheduled For November 5, 2025 - benzinga.com electroCore Announces Its GammaCore Sapphire Non-Invasive Vagus Nerve Stimulation Device Has Been Included In Long-Term Reimbursement Policy By Belgium's National Institute For Health And Disability Insurance electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com electroCore Q2 EPS $(0.44) Misses $(0.31) Estimate, Sales $7.381M Beat $7.219M Estimate electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.31) by 43.32 percent. This is a 15.79 percent decrease over losses of…
- benzinga.com Earnings Scheduled For August 6, 2025
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com electroCore Q1 EPS $(0.47) Misses $(0.35) Estimate, Sales $6.72M Miss $7.68M Estimate electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.35) by 34.29 percent. This is a 11.32 percent increase over losses of…
- benzinga.com Earnings Scheduled For May 7, 2025
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com HC Wainwright & Co. Reiterates Buy on electroCore, Maintains $25 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates electroCore (NASDAQ:ECOR) with a Buy and maintains $25 price target.
- benzinga.com Earnings Scheduled For March 12, 2025
- benzinga.com ElectroCore Announces Issuance Of 2 U.S. Patents Entitled "Devices And Methods For Vagal Nerve Stimulation"; "Devices And Methods For Remote Therapy And Patient Monitoring" electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received two patent issue notifications from the United States Patent and…
- benzinga.com electroCore Announces That It Has Received 5 Patent Issue Notifications From The U.S. Patent And Trademark Office Between December 17-31, 2024 electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received five patent issue notifications from the United States Patent and…
- benzinga.com HC Wainwright & Co. Maintains Buy on electroCore, Raises Price Target to $25 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains electroCore (NASDAQ:ECOR) with a Buy and raises the price target from $22 to $25.
- benzinga.com electroCore Enters Definitive Deal To Acquire NeuroMetrix, Including Its Quell Platform The transaction has been unanimously approved by the boards of directors of both companies and is expected to close around the end of the first quarter of 2025.ECOR will purchase all of the…
- benzinga.com electroCore Q3 2024 GAAP EPS $(0.31) Beats $(0.34) Estimate, Sales $6.554M Beat $6.493M Estimate electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.34) by 8.82 percent. This is a 54.41 percent increase over losses of $(0.68)…
- benzinga.com Earnings Scheduled For November 13, 2024
- benzinga.com Earnings Scheduled For March 13, 2024 Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
- benzinga.com Earnings Scheduled For November 8, 2023 Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.